Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The Democratic Party’s socialist wing is taking a victory lap after more than a dozen Democratic Socialists of America, or DSA, backed candidates won or are expected to advance in primaries across ...

New York City Mayor Zohran Mamdani endorsed a slate of five state legislative candidates on Saturday, just two days after he endorsed an insurgent challenger to Rep. Adriano Espaillat on the same ...

Controversial social media posts by socialist Congressional contender for Manhattan, Darializa Avila Chevalier, that criticized U.S. service members have resurfaced. Avila Chevalier, a member of the ...

Artificial intelligence (AI) may not be building better versions of itself yet, but Anthropic says the world is moving closer to that possibility than many people realize. In a new research paper ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.